FDA, Approval

FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight

Veröffentlicht: 07.08.2025 um 18:07 Uhr, prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom


+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/fda-approval-of-amgens-uplizna-for-igg4-related-disease-opens-new-market-opportunity-in-rare-autoimmune-segment--delveinsight-302427347.html

en | boerse | 67939958 |